Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer

Core Insights - Agios Pharmaceuticals has granted inducement equity awards to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan, as part of his employment agreement [1][2] Group 1: Inducement Grants - The inducement grants include a nonstatutory option to purchase up to 55,374 shares of common stock, restricted stock units for 24,300 shares, and performance stock units for 16,200 shares [2] - The option has an exercise price of $33.95 per share, which is the closing price of the company's common stock on March 5, 2025, and has a ten-year term with a four-year vesting schedule [2] - Restricted stock units will vest in equal annual installments over three years, while performance stock units are contingent on achieving specified performance milestones [2] Group 2: Company Overview - Agios Pharmaceuticals is a leader in pyruvate kinase (PK) activation, focusing on developing therapies for rare diseases [3] - The company markets a first-in-class PK activator for adults with PK deficiency, which is the first disease-modifying therapy for this condition [3] - Agios is advancing a clinical pipeline that includes investigational medicines for alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes-associated anemia, and phenylketonuria [3]